Principles of cancer genetics

Principles of Cancer Genetics

Volumn , Issue , 2008, Pages 1-325

  Bunz, Fred ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900969726     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-6784-6     Document Type: Book

References (141)

1. Antonarakis, S. E., Krawczak, M. & Cooper, D. N. Disease-causing mutations in the human genome. Eur. J. Pediatr. 159 Suppl 3, S173-S178 (2000).
2. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
3. De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 7, 256-269 (2007).
4. Fearnhead, N. S., Wilding, J. L. & Bodmer, W. F. Genetics of colorectal cancer: Hereditary aspects and overview of colorectal tumorigenesis. Br. Med. Bull. 64, 27-43 (2002).
5. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
6. Gatenby, R. A. & Vincent, T. L. An evolutionary model of carcinogenesis. Cancer Res. 63, 6212-6220 (2003).
7. Haber, D. A. & Settleman, J. Cancer: Drivers and passengers. Nature 446, 145-146 (2007).
8. Hollstein, M. et al. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 431, 199-209 (1999).
9. Kamp, D. W. & Weitzman, S. A. The molecular basis of asbestos induced lung injury. Thorax 54, 638-652 (1999).
10. Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007).
11. Klein, C. A. Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. Proc. Nat. Acad. Sci. USA 103, 18033-18034 (2006).
12. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924-935 (2006).
13. Modica-Napolitano, J. S., Kulawiec, M. & Singh, K. K. Mitochondria and human cancer. Curr. Mol. Med. 7, 121-131 (2007).
14. Nowell, P. C., Rowley, J. D. & Knudson, A. G., Jr. Cancer genetics, cytogenetics - defining the enemy within. Nat. Med. 4, 1107-1111 (1998).
15. Rafnar, T. et al. The Icelandic Cancer Project - a population-wide approach to studying cancer. Nat. Rev. Cancer 4, 488-492 (2004).
16. Scadden, D. T. Cancer stem cells refined. Nat. Immunol. 5, 701-703 (2004).
17. Smallbone, K., Gatenby, R. A., Gillies, R. J., Maini, P. K. & Gavaghan, D. J. Metabolic changes during carcinogenesis: Potential impact on invasiveness. J. Theor. Biol. 244, 703-713 (2007).
18. Smela, M. E., Currier, S. S., Bailey, E. A. & Essigmann, J. M. The chemistry and biology of aflatoxin B (1): From mutational spectrometry to carcinogenesis. Carcinogenesis 22, 535-545 (2001).
19. Spencer, S. L. et al. Modeling somatic evolution in tumorigenesis. PLoS Comput. Biol. 2, e108 (2006).
20. Stein, L. D. Human genome: End of the beginning. Nature 431, 915-916 (2004).
21. Weinberg, R. A. How cancer arises. Sci. Am. 275, 62-70 (1996).
22. Willingham, A. T. & Gingeras, T. R. TUF love for 'junk' DNA. Cell 125, 1215-1220 (2006).
23. Bishop, J. M. Enemies within: The genesis of retrovirus oncogenes. Cell 23, 5-6 (1981).
24. Epstein, M. A. Historical background. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 413-420 (2001).
25. Garraway, L. A. & Sellers, W. R. Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 6, 593-602 (2006).
26. Martin, G. S. The road to Src. Oncogene 23, 7910-7917 (2004).
27. Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233-245 (2007).
28. Rowley, J. D. Chromosome translocations: Dangerous liaisons revisited. Nat. Rev. Cancer 1, 245-250 (2001).
29. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340 (1999).
30. Schwab, M. Oncogene amplification in solid tumors. Semin. Cancer Biol. 9, 319-325 (1999).
31. Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
32. Weinberg, R. A. The cat and mouse games that genes, viruses, and cells play. Cell 88, 573-575 (1997).
33. Collins, F. S. Positional cloning moves from perditional to traditional. Nat Genet. 9, 347-350 (1995).
34. de la Chapelle, A. Genetic predisposition to colorectal cancer. Nat. Rev. Cancer 4, 769-780 (2004).
35. Dyer, M. A. & Bremner, R. The search for the retinoblastoma cell of origin. Nat. Rev. Cancer 5, 91-101 (2005).
36. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer (2007).
37. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
38. Kinzler, K. W. & Vogelstein, B. Landscaping the cancer terrain. Science 280, 1036-1037 (1998).
39. Marx, S. J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat. Rev. Cancer 5, 367-375 (2005).
40. Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2:1994 and beyond. Nat. Rev. Cancer 4, 665-676 (2004).
41. Sharpless, N. E. & De Pinho, R. A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22-30 (1999).
42. Soussi, T., Ishioka, C., Claustres, M. & Beroud, C. Locus-specific mutation databases: Pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 6, 83-90 (2006).
43. Ahmed, M. & Rahman, N. ATM and breast cancer susceptibility. Oncogene 25, 5906-5911 (2006).
44. Andressoo, J. O., Hoeijmakers, J. H. & Mitchell, J. R. Nucleotide excision repair disorders and the balance between cancer and aging. Cell. Cycle 5, 2886-2888 (2006).
45. Cahill, D. P., Kinzler, K. W., Vogelstein, B. & Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9, M57-M60 (1999).
46. Cleaver, J. E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. Cancer 5, 564-573 (2005).
47. Duesberg, P. Does aneuploidy or mutation start cancer? Science 307, 41 (2005).
48. de Laat, W. L., Jaspers, N. G. & Hoeijmakers, J. H. Molecular mechanism of nucleotide excision repair. Genes Dev. 13, 768-785 (1999).
49. Ellis, N. A. Mutation-causing mutations. Nature 381, 110-111 (1996).
50. Ellis, N. A. & German, J. Molecular genetics of Bloom's syndrome. Hum. Mol. Genet. 5, 1457-1463 (1996).
51. Fearon, E. R. Human cancer syndromes: Clues to the origin and nature of cancer. Science 278, 1043-1050 (1997).
52. Gatti, R. A. The inherited basis of human radiosensitivity. Acta Oncol. 40, 702-711 (2001).
53. Gurtan, A. M. & D'Andrea, A. D. Dedicated to the core: Understanding the Fanconi anemia complex. DNA Repair 5, 1119-1125 (2006).
54. Joenje, H. & Patel, K. J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2, 446-457 (2001).
55. Kastan, M. B. & Lim, D. S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-86. (2000).
56. Kipling, D., Davis, T., Ostler, E. L. & Faragher, R. G. What can progeroid syndromes tell us about human aging? Science 305, 1426-1431 (2004).
57. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-69. (1998).
58. Margolis, R. L. Tetraploidy and tumor development. Cancer Cell 8, 353-354 (2005).
59. Michor, F., Iwasa, Y., Vogelstein, B., Lengauer, C. & Nowak, M. A. Can chromosomal instability initiate tumorigenesis? Semin. Cancer Biol. 15, 43-49 (2005).
60. Modrich, P. Mismatch repair, genetic stability, and cancer. Science 266, 1959-1960 (1994).
61. Mohaghegh, P. & Hickson, I. D. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. Hum. Mol. Genet. 10, 741-746 (2001).
62. Rajagopalan, H. & Lengauer, C. Aneuploidy and cancer. Nature 432, 338-341 (2004).
63. Rajagopalan, H., Nowak, M. A., Vogelstein, B. & Lengauer, C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 3, 695-701 (2003).
64. Shiloh, Y. The ATM-mediated DNA-damage response: Taking shape. Trends Biochem. Sci. 31, 402-410 (2006).
65. Tomlinson, I. & Bodmer, W. Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nat. Med. 5, 11-12 (1999).
66. Bakkenist, C. J. & Kastan, M. B. Initiating cellular stress responses. Cell 118, 9-17 (2004).
67. Bensaad, K. & Vousden, K. H. P53: New roles in metabolism. Trends Cell Biol. 17, 286-291 (2007).
68. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
69. Cohen, P. The origins of protein phosphorylation. Nat. Cell Biol. 4, E127-E130 (2002).
70. Dang, V. V. et al. The c-Myc target gene network. Semin Cancer Biol. 16, 253-264 (2006).
71. Giaccia, A. J. & Kastan, M. B. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev. 12, 2973-2983 (1998).
72. Giacinti, C. & Giordano, A. RB and cell cycle progression. Oncogene 25, 5220-5227 (2006).
73. Hajra, K. M. & Fearon, E. R. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34, 255-268 (2002).
74. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
75. Horn, H. F. & Vousden, K. H. Coping with stress: Multiple ways to activate p53. Oncogene 26, 1306-1316 (2007).
76. Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316-323 (2004).
77. Kastan, M. B. & Lim, D. S. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-86 (2000).
78. Linding, R. et al. Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415-1426 (2007).
79. Massague, J. & Gomis, R. R. The logic of TGFbeta signaling. FEBS Lett. 580, 2811-2820 (2006).
80. Nelson, W. J. & Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483-1487 (2004).
81. Polakis, P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17, 45-51 (2007).
82. Samuels, Y. & Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77-82 (2006).
83. Sansal, I. & Sellers, W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954-2963 (2004).
84. Scott, J. D. & Pawson, T. Cell communication: The inside story. Sci. Am. 282, 72-79 (2000).
85. Sears, R. C. The life cycle of C-myc: From synthesis to degradation. Cell. Cycle 3, 1133-1137 (2004).
86. Shields, J. M., Pruitt, K., McFall, A., Shaub, A. & Der, C. J. Understanding Ras: 'It ain't over 'til it's over'. Trends Cell Biol. 10, 147-154 (2000).
87. Simpson, L. & Parsons, R. PTEN: Life as a tumor suppressor. Exp. Cell Res. 264, 29-41 (2001).
88. Toledo, F. & Wahl, G. M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 (2006).
89. Venkitaraman, A. R. Medicine: Aborting the birth of cancer. Nature 434, 829-830 (2005).
90. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
91. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004).
92. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
93. Vousden, K. H. & Lane, D. P. P53 in Health and Disease. Nat. Rev. Mol. Cell Biol. 8, 275-283 (2007).
94. Zhao, J. J. & Roberts, T. M. PI3 kinases in cancer: From oncogene artifact to leading cancer target. Sci. STKE 2006, e52 (2006).
95. Zhou, B. B. & Elledge, S. J. The DNA damage response: Putting checkpoints in perspective. Nature 408, 433-439 (2000).
96. Bell, D. A. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 18(Suppl 2), S19-S32 (2005).
97. de Snoo, F. A. & Hayward, N. K. Cutaneous melanoma susceptibility and progression genes. Cancer Lett. 230, 153-186 (2005).
98. Ellenson, L. H. & Wu, T. C. Focus on endometrial and cervical cancer. Cancer Cell 5, 533-538 (2004).
99. El-Rifai, W. & Powell, S. M. Molecular biology of gastric cancer. Semin. Radiat. Oncol. 12, 128-140 (2002).
100. Farazi, P. A. & De Pinho, R. A. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat. Rev. Cancer 6, 674-687 (2006).
101. Gallia, G. L. et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol. Cancer Res. 4, 709-714 (2006).
102. Haluska, F. G. et al. Genetic alterations in signaling pathways in melanoma. Clin. Cancer Res. 12, 2301s-2307s (2006).
103. Hovey, R. M. et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 58, 3555-3560 (1998).
104. Hussain, S. P., Schwank, J., Staib, F., Wang, X. W. & Harris, C. C. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene 26, 2166-2176 (2007).
105. Kangelaris, K. N. & Gruber, S. B. Clinical implications of founder and recurrent CDH1 mutations in hereditary diffuse gastric cancer. JAMA 297, 2410-2411 (2007).
106. Kondo, T., Ezzat, S. & Asa, S. L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6, 292-306 (2006).
107. Linehan, W. M., Walther, M. M. & Zbar, B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163-2172 (2003).
108. Maitra, A., Kern, S. E. & Hruban, R. H. Molecular pathogenesis of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 20, 211-226 (2006).
109. Moasser, M. M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007).
110. Munger, K. et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78, 11451-11460 (2004).
111. Nakayama, K. et al. Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer 120, 2613-2617 (2007).
112. Nathanson, K. L., Wooster, R. & Weber, B. L. Breast cancer genetics: What we know and what we need. Nat. Med. 7, 552-556 (2001).
113. Nylander, K., Dabelsteen, E. & Hall, P. A. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J. Oral Pathol. Med. 29, 413-425 (2000).
114. Oda, K., Stokoe, D., Taketani, Y. & McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65, 10669-10673 (2005).
115. Ohgaki, H. & Kleihues, P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170, 1445-1453 (2007).
116. Sagaert, X., De Wolf-Peeters, C., Noels, H. & Baens, M. The pathogenesis of MALT lymphomas: Where do we stand? Leukemia 21, 389-396 (2007).
117. Warnakulasuriya, K. A. & Ralhan, R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco - a review. J. Oral Pathol. Med. 36, 63-77 (2007).
118. Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843 (2003).
119. Domchek, S. M. & Weber, B. L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25, 5825-5831 (2006).
120. Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36 (2002).
121. Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313 (2005).
122. Guttmacher, A. E. & Collins, F. S. Realizing the promise of genomics in biomedical research. JAMA 294, 1399-1402 (2005).
123. Herbst, R. S., Fukuoka, M. & Baselga, J. Gefitinib - a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965 (2004).
124. Hu, Y. C., Sidransky, D. & Ahrendt, S. A. Molecular detection approaches for smoking associated tumors. Oncogene 21, 7289-7297 (2002).
125. Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
126. Kelley, S. K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333-339 (2004).
127. Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005).
128. Lacroix, M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer 13, 1033-1067 (2006).
129. Mao, L. et al. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. U. S. A. 91, 9871-9875 (1994).
130. Mills, N. E. et al. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J. Natl. Cancer Inst. 87, 1056-1060 (1995).
131. Morgensztern, D. & Govindan, R. Is there a role for cetuximab in non small cell lung cancer? Clin. Cancer Res. 13, 4602s-4605s (2007).
132. Nahta, R. & Esteva, F. J. Trastuzumab: Triumphs and tribulations. Oncogene 26, 3637-3643 (2007).
133. Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P. & Olivier, M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165 (2007).
134. Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
135. Schwartz, R. S. A needle in a haystack of genes. N. Engl. J. Med. 346, 302-304 (2002).
136. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
137. Trepanier, A. et al. Genetic cancer risk assessment and counseling: Recommendations of the national society of genetic counselors. J. Genet. Couns. 13, 83-114 (2004).
138. Wang, S. & El-Deiry, W. S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22, 8628-8633 (2003).
139. Wexler, N. S. The Tiresias complex: Huntington's disease as a paradigm of testing for late-onset disorders. FASEB J. 6, 2820-2825 (1992).
140. Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P. A. & Stratton, M. R. COSMIC 2005. Br J Cancer 94, 318-322 (2006). http://www.sanger.ac.uk/genetics/ CGP/cosmic
141. Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. A census of human cancer genes. Nat Rev Cancer 4, 177-183 (2004).